It was clinically approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) in 2014 for the treatment of relapsing-remitting multiple sclerosis (MS), showing a significant efficacy over 2 years versus placebo and a favorable benefit-risk profile in two phase-III clinical trials, although with several adverse effects such as nausea, diarrhea, abdominal pain and leukopenia in some patients [282, 283]
Symptoms of AFS will depend on where the imbalance is occurring in the NEM system
It drives physical development, builds muscle, and controls sex drive, primarily in males, but it also supports health in females
Typically within 2448 hours after you submit your intake.
Systematic investigation of combination approaches would establish evidence-based protocols integrating BPC-157 into comprehensive treatment strategies
What was the original focus of BPC 157 research